Canopy Growth Just Topped Earnings Estimates. Should You Buy, Sell, or Hold CGC Stock for November 2025?

Core Insights - Canopy Growth's stock surged 7.34% following the release of its Q2 fiscal 2026 results, indicating strong investor interest [1] - The company outperformed analyst forecasts, driven by robust performance in the Canadian adult-use and medical cannabis segments [2] - Operational improvements and disciplined cost management contributed to narrowing losses and lifting gross margins [2] Company Performance - Canopy Growth's Canadian operations continued to grow despite supply chain challenges in Europe, supported by innovative vape products and an increase in medical cannabis patients [3] - The company's evolving strategy and resilience in core markets are highlighted by these results [3] - The stock's future performance will depend on sustaining margin expansion, strengthening international operations, and solidifying its medical leadership [4] Market Position - Canopy Growth, based in Smiths Falls, Canada, has a market cap of approximately $287 million and serves both medical and recreational cannabis markets [5] - The product lineup includes high-THC cannabis flower, infused pre-rolls, advanced vape technology, and cannabis edibles [5] - Despite a strong product portfolio, CGC shares have declined 70.18% over the past 52 weeks, with a 14% drop in the last month, contrasting with a 14.4% gain in the S&P 500 Index during the same period [6]